ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Abatacept"

  • Abstract Number: 609 • 2017 ACR/ARHP Annual Meeting

    Body Mass Index Does Not Influence the Efficacy of Subcutaneous Abatacept in Patients with Psa: Results from a Phase III Trial

    Iain B. McInnes1, Gianfranco Ferraccioli2, MA D'Agostino3, M Le Bars4, S Banerjee5, H Ahmad5, Y Elbez6, J Ye5 and Philip J Mease7, 1University of Glasgow, Glasgow, Great Britain, 2Division of Rheumatology - Institute of Rheumatology and Affine Sciences, Catholic University of the Sacred Heart, Rome, Italy, 3Hôpital Ambroise Paré, Boulogne-Billancourt, France, 4Bristol-Myers Squibb, Rueil-Malmaison, France, 5Bristol-Myers Squibb, Princeton, NJ, 6Excelya, Boulogne-Billancourt, France, 7Swedish Medical Center and University of Washington, Seattle, WA

    Background/Purpose: Obesity is a risk factor for the development and severity of psoriatic arthritis (PsA).1,2 Patients (pts) with increased BMI (overweight/obese) are less likely to…
  • Abstract Number: 1424 • 2017 ACR/ARHP Annual Meeting

    Impact of Glucocorticoid Therapy on the Efficacy of SC Abatacept or Adalimumab in RA Patients with Inadequate Response to MTX: A Post Hoc Analysis of Data from a Head-to-Head Trial

    Yannick Degboé1,2, Michael Schiff3, Michael Weinblatt4, Roy Fleischmann5, HA Ahmad6 and Arnaud Constantin2,7, 1Toulouse University Hospital, Toulouse, France, 2Université Paul Sabatier, Toulouse, France, 3University of Colorado, Denver, CO, 4Brigham and Women’s Hospital, Boston, MA, 5University of Texas Southwestern Medical Center, Dallas, TX, 6Bristol-Myers Squibb, Princeton, NJ, 7Purpan University Hospital, Toulouse, France

    Background/Purpose: In patients with RA, low-dose glucocorticoids (GCs) have been shown to increase clinical, functional and radiographic efficacy when combined with conventional synthetic DMARDs;1 however,…
  • Abstract Number: 1429 • 2017 ACR/ARHP Annual Meeting

    Incidence Rates of Adverse Events with Death As an Outcome during Abatacept Treatment in RA: Results from an Integrated Data Analysis from 16 Clinical Trials

    D Fleming1, TA Simon1, A Torbeyns2, U Meier-Kriesche1 and A Johnsen1, 1Bristol-Myers Squibb, Princeton, NJ, 2Bristol-Myers Squibb, Braine l’Alleud, Belgium

    Background/Purpose: Patients with RA have a 1.5–2-fold increased risk of mortality compared with the general population. The association between mortality rates and different RA treatments…
  • Abstract Number: 1468 • 2017 ACR/ARHP Annual Meeting

    Abatacept Retention Rates, Overall and By Participating Country, and Prognostic Factors of Retention in Patients with RA: 2-Year Results from a Real-World Observational Study

    Rieke Alten1, HM Lorenz2, X Mariette3, HG Nüßlein4, M Galeazzi5, F Navarro6, M Chartier7, Y Elbez8, C Rauch9 and M Le Bars7, 1Schlosspark-Klinik University Medicine, Berlin, Germany, 2University Hospital, Heidelberg, Germany, 3Université Paris-Sud, Paris, France, 4University of Erlangen, Nürnberg, Germany, 5University of Siena, Siena, Italy, 6Hospital Universitario Virgen Macarena, Seville, Spain, 7Bristol-Myers Squibb, Rueil-Malmaison, France, 8Excelya, Boulogne-Billancourt, France, 9Bristol-Myers Squibb, Munich, Germany

    Background/Purpose: ACTION (NCT02109666) was the first prospective international non-interventional study designed to provide long-term real-world data on abatacept retention in patients (pts) with RA. The…
  • Abstract Number: 1469 • 2017 ACR/ARHP Annual Meeting

    Treatment Paradigms in Real-World Practice: Biologic Agent Use Prior to and after Discontinuation of Abatacept

    Rieke Alten1, H-M Lorenz2, X Mariette3, H Nüßlein4, M Galeazzi5, F Navarro6, M Chartier7, Y Elbez8, C Rauch9 and M Le Bars7, 1Schlosspark-Klinik University Medicine, Berlin, Germany, 2University Hospital, Heidelberg, Germany, 3Université Paris-Sud, Paris, France, 4University of Erlangen-Nuremberg, Nuremberg, Germany, 5University of Siena, Siena, Italy, 6Hospital Universitario Virgen Macarena, Seville, Spain, 7Bristol-Myers Squibb, Rueil-Malmaison, France, 8Excelya, Boulogne-Billancourt, France, 9Bristol-Myers Squibb, Munich, Germany

    Background/Purpose: ACTION is a 2-year, observational study of patients (pts) with moderate-to-severe RA who initiated IV abatacept in Canada and Europe (NCT02109666). The objective was…
  • Abstract Number: 1817 • 2017 ACR/ARHP Annual Meeting

    Abatacept Shows Better Sustainability Than TNF Inhibitors When Used Following Initial Biologic DMARD Failure in the Treatment of RA: 8 Years of Real-World Observations from the Rhumadata® Clinical Database and Registry

    Denis Choquette1, L Bessette2, E Alemao3, B Haraoui4, F Massicotte1, M Mtibaa5, E Muratti5, Jean-Pierre Pelletier1, R Postema6, Jean-Pierre Raynauld7, M-A Rémillard8, D Sauvageau1, A Turcotte9, É Villeneuve1 and L Coupal10, 1Rheumatology, Institut de Recherche en Rhumatologie de Montréal (IRRM), Montréal, QC, Canada, 2Centre d'ostéoporose et de rhumatologie de Québec (CORQ), Québec, QC, Canada, 3Bristol-Myers Squibb, Princeton, NJ, 4Institut de Recherche en Rhumatologie de Montréal (IRRM), Montreal, QC, Canada, 5Bristol-Myers Squibb, Montréal, QC, Canada, 6Bristol-Myers Squibb, Uxbridge, United Kingdom, 7Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Montreal, QC, Canada, 8Rheumatology, Institut de Recherche en Rhumatologie de Montréal (IRRM), Montreal, QC, Canada, 9Rheumatology, Centre d’Ostéoporose et de Rhumatologie de Québec (CORQ), Québec, QC, Canada, 10Institut de Recherche en Rhumatologie de Montréal (IRRM), Montréal, QC, Canada

    Background/Purpose: In the absence of biomarkers predicting response to a specific therapy, the choice of second biologic is based mostly on habit and availability of…
  • Abstract Number: 2272 • 2017 ACR/ARHP Annual Meeting

    Long-Term Effectiveness and Safety of Abatacept in Juvenile Idiopathic Arthritis: Ongoing Results from the Abatacept in JIA Registry

    Daniel J Lovell1, N Ruperto2, N Tzaribachev3, A Zeft4, Rolando Cimaz5, V Stanevica6, Gerd Horneff7, John F. Bohnsack8, Thomas A. Griffin9, R Carrasco10, Maria Trachana11, Jason A Dare12, I Foeldvari13, Richard K Vehe14, TA Simon15, Hermine I. Brunner16 and Alberto Martini2, 1Cincinnati Children’s Hosp. Medical Center, Cincinnati, OH, 2Istituto G. Gaslini Pediatria II Reumatologia, Genova, Italy, 3University Medical Center Schleswig-Holstein, Bad Bramstedt, Germany, 4Cleveland Clinic, Cleveland, OH, 5Azienda Ospedaliero-Universitaria Meyer, Florence, Italy, 6Riga Stradins University, Riga, Latvia, 7Asklepios Klinik Zentrum für Allgemeine Paediatrie und Neonatologie, Sankt Augustin, Germany, 8University of Utah School of Medicine, Salt Lake City, UT, 9Levine Children’s Hospital at Carolinas Medical Center, Charlotte, NC, 10Specially For Children, Austin, TX, 11Hippokration General Hospital, Thessaloniki, Greece, 12University of Arkansas for Medical Sciences, Little Rock, AR, 13Hamburg Centre for Pediatric Rheumatology, Hamburg, Germany, 14University of Minnesota, Minneapolis, MN, 15Bristol-Myers Squibb, Princeton, NJ, 16Cincinnati Children's Hospital Medical Center, Cincinnati, OH

    Background/Purpose: Abatacept is an FDA- and EMA-approved biologic that is widely used in children with juvenile idiopathic arthritis (JIA). The purpose of this long-term ongoing…
  • Abstract Number: 2450 • 2017 ACR/ARHP Annual Meeting

    Comparative Effectiveness of Abatacept Versus TNFi in Patients with RA Who Are CCP+ in the United States Corrona Registry

    Leslie R Harrold1, Heather J. Litman2, SE Connolly3, E Alemao3, K Price3, S Kelly3, Sabrina Rebello4, W Hua2 and Joel Kremer5, 1University of Massachusetts, Worcester, MA, 2Corrona, Southborough, MA, 3Bristol-Myers Squibb, Princeton, NJ, 4Corrona, LLC, Southborough, MA, 5Albany Medical College and The Center for Rheumatology, Albany, NY

    Background/Purpose: Anti-cyclic citrullinated peptide positivity (CCP+) is associated with a better response to abatacept than anti-CCP negativity in patients with RA1,2; however, there are no…
  • Abstract Number: 2452 • 2017 ACR/ARHP Annual Meeting

    In Real-World Clinical Practice, Patients Switching from IV to SC Abatacept Maintain Clinical Efficacy after Switch

    Rieke Alten1, HM Lorenz2, X Mariette3, H Nüßlein4, M Galeazzi5, F Navarro6, M Chartier7, J Heitzmann8, C Rauch9 and M Le Bars7, 1Schlosspark-Klinik University Medicine, Berlin, Germany, 2University Hospital, Heidelberg, Germany, 3Université Paris-Sud, Paris, France, 4University of Erlangen-Nuremberg, Nuremberg, Germany, 5University of Siena, Siena, Italy, 6Hospital Universitario Virgen Macarena, Seville, Spain, 7Bristol-Myers Squibb, Rueil-Malmaison, France, 8Excelya, Boulogne-Billancourt, France, 9Bristol-Myers Squibb, Munich, Germany

    Background/Purpose: Patients (pts) with RA may be able to switch from IV to SC abatacept with no loss of efficacy or safety concerns, but data…
  • Abstract Number: 419 • 2017 ACR/ARHP Annual Meeting

    Abatacept Initiation in Chilean Patients with Long Lasting Rheumatoid Arthritis. Hospital Padre Hurtado Experience

    Omar Valenzuela1, María Paz Poblete2, Claudia Mardones2, Sebastián Ibáñez1, Katherine Mogollones2, Francisco Silva1 and María José Villar2, 1Rheumatology department, Hospital Padre Hurtado, Santiago, Chile, 2Hospital Padre Hurtado, Santiago, Chile

    Background/Purpose: Since the year 2016 Rheumatoid Arthritis (RA) patients in the Chilean public health system can access biologic treatment if they have active disease refractory…
  • Abstract Number: 2491 • 2017 ACR/ARHP Annual Meeting

    Real-World Effectiveness and Safety of Subcutaneous Abatacept in Biologic-Naive Vs. Biologic-Experienced RA Patients: The Abatacept Best Care Study

    B Haraoui1, Janet E. Pope2, Isabelle Fortin3, Emmanouil Rampakakis4, John S. Sampalis5,6, Francoise Romeyer7, Joseph Atallah7 and Louis Bessette8, 1Institut de Recherche en Rhumatologie de Montréal (IRRM), Montreal, QC, Canada, 2Department of Medicine, Division of Rheumatology, University of Western Ontario, St Joseph's Health Care, London, ON, Canada, 3Centre de Rhumatologie de l'Est du Quebec, Rimouski, QC, Canada, 4JSS Medical Research, Montreal, QC, Canada, 5McGill University, Montreal, QC, Canada, 6JSS Medical Research, St-Laurent, QC, Canada, 7Bristol-Myers Squibb, Montreal, QC, Canada, 8Centre d'Osteoporose et de Rhumatologie de Quebec, Quebec, QC, Canada

    Background/Purpose: The efficacy and safety of subcutaneous (SC) abatacept in the management of rheumatoid arthritis (RA) has been demonstrated in numerous controlled clinical trials. However,…
  • Abstract Number: 498 • 2017 ACR/ARHP Annual Meeting

    Response to Abatacept of Different Patterns of Interstitial Lung Disease in Rheumatoid Arthritis. Multicenter Study of 63 Patients

    Carlos Fernández-Díaz1, Santos Castañeda2, Clara Ojeda-Garcia3, Alejandro Olivé4, Patricia Carreira5, Trinidad Perez Sandoval6, Miriam Retuerto Guerrero7, Evelin Cecilia Cervantes Pérez8, Samantha Rodriguez9, Bryan Josue Robles Flores10, Blanca Hernández-Cruz11, Ana Urruticoechea-Arana12, Olga Maiz13, Desiree Palma14, Luis Arboleya15, Gema Bonilla16, Manuel Rodríguez-Gómez17, Concepción Delgado18, Rosa Expósito19, Ana Ruibal Escribano20, Juan Blanco Madrigal21, José Antonio Bernal22, Paloma Vela23, Belen Alvarez-Rodriguez24, María Concepción Fito Manteca25, Javier Narváez26, Manuel Jose Moreno27, Mireia López-Corbeto28, Natalia Mena-Vazquez29, S. Romero-Yuste30, Clara Aguilera-Cros31, Sergi Ordoñez32, Ignacio Villa-Blanco33, Nuria Vegas-Revenga1, Victor Mora-Cuesta34, Javier Loricera1, Miguel Angel González-Gay1, José Luis Hernandez35 and Ricardo Blanco1, 1Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, 2Hospital Universitario de La Princesa, Madrid. Spain, Madrid, Spain, 3Rheumatology, Hospital Virgen de la Macarena, Sevilla, Spain, 4Rheumatology, Hospital Germans Trias i Pujol, Badalona, Spain, 5Department of Rheumatology, Hospital Universitario 12 de Octubre, Madrid, Spain, 6Rheumatology, Hospital de León, LEÓN, Spain, 7Rheumatology, Hospital de León, Leon, Spain, 8Rheumatology, Hospital Santiago de Compostela, Santiago de Compostela, Spain, 9H. German Trias., Barcelona, Spain, 10Rheumatology, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain, 11Rheumatology, Hospital Universitario Virgen Macarena, Sevilla, Spain, 12Rheumatology Department. Hospital Can Misses, IBIZA, Spain, 13Hospital Donostia. Spain, San Sebastian, Spain, 14Rheumatology, Rafael Mendez Hospital, Spain., Lorca (Murcia), Spain, 15Rheumatology, Hospital Universitario Central de Asturias, Oviedo, Spain, 16Hospital Universitario La Paz, Madrid, Spain, 17Complejo Hospitalario Universitario de Ourense, Ourense, Spain, 18H. Clínico Universitario Lozano Blesa, Zaragoza, Spain, 19Rheumatology, Hospital Comarcal de Laredo. Spain, Laredo, Spain, 20Rheumatology, Hospital Universitario de Araba, Vittoria, Spain, 21Rheumatology, Hospital de Basurto, BIlbao, Spain, 22Reumatología, Hospital Universitario del Vinalopó, Elche, Spain, 23Reumatología, Hospital General Universitario de Alicante. Alicante. Spain, Alicante, Spain, 24Hospital Txagorritxu, Vittoria, Spain, 25Reumatología, Hospital de Navarra, Pamplona, Spain, 26Rheumatology Department, Hospital de Bellvitge. Barcelona. Spain, L’Hospitalet de Llobregat, Spain, 27Rheumatology, Hospital Virgen de la Arrixaca, MURCIA, Spain, 28Hospital Universitario Vall d´Hebron, Barcelona, Spain, 29Rheumatology, Hospital Universitario de Malaga, Malaga, Spain, 30H. Pontevedra, Pontevedra, Spain, 31Rheumatology, Hospital Virgen del Rocio, Sevilla, Spain, 32Hospital Universitario Arnau de Vilanova, Vilanova, Spain, 33Hospital de Sierrallana, Sierrallana, Spain, 34Neumology, Hospital Universitario Marqués de Valdecilla, IDIVAL,, Santander, Spain, 35Division of Internal Medicine., Hospital Universitario Marqués de Valdecilla, IDIVAL,, Santander, Spain

    Background/Purpose: Disease modifying antirheumatic drugs (DMARD) such as methotrexate (MTX), ) or antiTNFα have been implicated in exacerbation of Interstitial lung disease (ILD)of rheumatoid arthritis…
  • Abstract Number: 2494 • 2017 ACR/ARHP Annual Meeting

    Analysis of the Efficacy, Safety and Continuation Rate of Abatacept in Elderly Patients with Rheumatoid Arthritis

    Mayumi Matsuda1, Yu Funakubo Asanuma2, Noritsune Kouzu3 and Toshihide Mimura2, 1Department of Rheumatology and Applied Immunology, Saitama Medical University, Moroyama-machi, Japan, 2Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Saitama, Japan, 3Saitama Medical University, Moroyama, Japan

    Background/Purpose: The elderly rheumatoid arthritis (RA) patients have declined physical performances and various complications. The efficacy of the biological DMARDs may decrease in elderly RA…
  • Abstract Number: 526 • 2017 ACR/ARHP Annual Meeting

    Comparative Pulmonary Safety of Abatacept and Tumor Necrosis Factor Inhibitors in Patients with RA and Chronic Pulmonary Condition

    Eun Ha Kang1, Yinzhu Jin2, Sara Dejene3, Gregory Brill3, Rishi J. Desai2, Jeffrey A. Sparks4 and Seoyoung C. Kim5, 1Division of Rheumatology, Department of Internal Medicine, Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea, Republic of (South), 2Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital, Boston, MA, 3Brigham and Women's Hospital, Boston, MA, 4Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 5Rheumatology, Immunology and Allergy; Pharmacoepidemiologyand Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA

    Background/Purpose: Patients with rheumatoid arthritis (RA) can have various pulmonary comorbidities including asthma, chronic obstructive pulmonary disease (COPD) and interstitial lung disease (ILD). Biologics can…
  • Abstract Number: 2786 • 2017 ACR/ARHP Annual Meeting

    Timing of Abatacept Infusions before Elective Arthroplasty and the Risk of Post-Operative Infection

    Michael D. George1, Joshua Baker2, Kevin Winthrop3, E Alemao4, Lang Chen5, SE Connolly4, TA Simon4, Qufei Wu6, Fenglong Xie7, Shuo Yang7 and Jeffrey R. Curtis8, 1Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, 2Rheumatology, University of Pennsylvania, Philadelphia, PA, 3Oregon Health Sciences University, Portland, OR, 4Bristol-Myers Squibb, Princeton, NJ, 5University of Alabama at Birmingham, Birmingham, AL, 6Biostatistics and Analysis Center, University of Pennsylvania, Philadelphia, PA, 7Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 8Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: Current guidelines recommend holding biologic DMARDs before major surgery, despite limited data. Few studies have examined perioperative timing of individual biologic therapies. This study…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • …
  • 12
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology